The Successful Use of Parenteral Methadone in a Patient with a Prolonged QTc Interval

Journal of Pain and Symptom Management

Volumn 34, Issue 5, 2007, Pages 566-569

  Sekine, Ryuichi ^a   Obbens, Eugenie A M T ^a   Coyle, Nessa ^a   Inturrisi, Charles E ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

cancer pain; Methadone; prolonged QTc interval; torsade de pointes (TdP)

Indexed keywords

ANTICONVULSIVE AGENT; CHLORBUTOL; GABAPENTIN; HYDROMORPHONE; INTERFERON; METHADONE; MORPHINE; OXYCODONE; STEROID;

ADD ON THERAPY; ADULT; ADVANCED CANCER; ANALGESIA; ARTICLE; BACKACHE; CANCER PAIN; CARDIOTOXICITY; CASE REPORT; CHRONIC PAIN; DECISION MAKING; DISEASE PREDISPOSITION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; PAIN ASSESSMENT; QT INTERVAL; QT PROLONGATION; RISK BENEFIT ANALYSIS; SPINE METASTASIS; TORSADE DES POINTES;

ANALGESICS, OPIOID; CARCINOMA, RENAL CELL; HUMANS; INFUSIONS, PARENTERAL; KIDNEY NEOPLASMS; LONG QT SYNDROME; MALE; METHADONE; MIDDLE AGED; PAIN, INTRACTABLE; PALLIATIVE CARE;

EID: 35448973995     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2007.05.001     Document Type: Article

References (23)

1. Katchman A.N., Koerner J., Tosaka T., Woosley R.L., and Ebert S.N. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther 316 (2006) 1098-1106
2. Kornick C.A., Kilborn M.J., Santiago-Palma J., et al. QTc interval prolongation associated with intravenous methadone. Pain 105 (2003) 499-506
3. Al-Khatib S.M., LaPointe N.M., Kramer J.M., and Califf R.M. What clinicians should know about the QT interval. JAMA 289 (2003) 2120-2127
4. Bolan E.A., Tallarida R.J., and Pasternak G.W. Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes. J Pharmacol Exp Ther 303 (2002) 557-562
5. Shimoyama N., Shimoyama M., Elliott K.J., and Inturrisi C.E. d-Methadone is antinociceptive in the rat formalin test. J Pharmacol Exp Ther 283 (1997) 648-652
6. Gorman A.L., Elliott K.J., and Inturrisi C.E. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 223 (1997) 5-8
7. Codd E.E., Shank R.P., Schupsky J.J., and Raffa R.B. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 274 (1995) 1263-1270
8. Crews J.C., Sweeney N.J., and Denson D.D. Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics. Cancer 72 (1993) 2266-2272
9. Fitzgibbon D.R., and Ready L.B. Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain 73 (1997) 259-261
10. Galer B.S., Coyle N., Pasternak G.W., and Portenoy R.K. Individual variability in the response to different opioids: report of five cases. Pain 49 (1992) 87-91
11. Manfredi P.L., Borsook D., Chandler S.W., and Payne R. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Pain 70 (1997) 99-101
12. Manfredi P.L., Gonzales G.R., Cheville A.L., Kornick C., and Payne R. Methadone analgesia in cancer pain patients on chronic methadone maintenance therapy. J Pain Symptom Manage 21 (2001) 169-174
13. Santiago-Palma J., Khojainova N., Kornick C., et al. Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl. Cancer 92 (2001) 1919-1925
14. Krantz M.J., Lewkowiez L., Hays H., et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 137 (2002) 501-504
15. Walker P.W., Klein D., and Kasza L. High dose methadone and ventricular arrhythmias: a report of three cases. Pain 103 (2003) 321-324
16. Gil M., Sala M., Anguera I., et al. QT prolongation and torsades de pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 92 (2003) 995-997
17. Katchman A.N., McGroary K.A., Kilborn M.J., et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J Pharmacol Exp Ther 303 (2002) 688-694
18. Inturrisi C.E., Colburn W.A., Kaiko R.F., Houde R.W., and Foley K.M. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 41 (1987) 392-401
19. Krantz M.J., Lowery C.M., Martell B.A., Gourevitch M.N., and Arnsten J.H. Effects of methadone on QT-interval dispersion. Pharmacotherapy 25 (2005) 1523-1529
20. Cruciani R.A., Sekine R., Homel P., et al. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 29 (2005) 385-391
21. Fredheim O.M., Borchgrevink P.C., Hegrenaes L., et al. Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: a prospective 9-month follow-up study. J Pain Symptom Manage 32 (2006) 180-185
22. Martell B.A., Arnsten J.H., Krantz M.J., and Gourevitch M.N. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 95 (2005) 915-918
23. Sticherling C., Schaer B.A., Ammann P., Maeder M., and Osswald S. Methadone-induced torsade de pointes tachycardias. Swiss Med Wkly 135 (2005) 282-285